3
Announcements
Trials
Browse
Landscape
Status
Completed
3
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
501
Carcinoma, Renal Cell
165
Urinary Bladder Neoplasms
135
Carcinoma, Transitional Cell
71
Carcinoma, Non-Small-Cell Lung
57
Kidney Neoplasms
56
Melanoma
53
Breast Neoplasms
51
Ovarian Neoplasms
43
Neoplasms
41
Neoplasm Metastasis
40
Colorectal Neoplasms
38
Lung Neoplasms
27
Squamous Cell Carcinoma of Head and Neck
26
Non-Muscle Invasive Bladder Neoplasms
26
Uterine Cervical Neoplasms
25
Stomach Neoplasms
25
Sarcoma
24
Endometrial Neoplasms
24
Triple Negative Breast Neoplasms
21
Pancreatic Neoplasms
19
Esophageal Neoplasms
18
Carcinoma, Hepatocellular
17
Wilms Tumor
16
Head and Neck Neoplasms
16
Small Cell Lung Carcinoma
15
Urologic Neoplasms
14
Colonic Neoplasms
14
Urethral Neoplasms
13
Ureteral Neoplasms
13
Interventions
enzalutamide
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Metastatic Hormone-sensitive Prostate Cancer
×
Genitourinary
×
Clear all
NCT05901649
2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled
NCT06874114
2026-04-13
RE-ENGAGE
Bayer
Active not recruiting
700 enrolled